Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta-Analysis
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta-Analysis
复制标题
DOI：
10.1016/j.clbc.2013.02.003
复制
发表时间：
2013-08-01
影响因子：
3.1
通讯作者：
Zhang, Yongxue
中科院分区：
文献类型：
--
作者：
Mghanga, Fabian Pius;Lan, Xiaoli;Zhang, Yongxue
本研究的目的是评估氟-18氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）在监测乳腺癌对新辅助化疗反应中的诊断作用。从 15 项研究的 745 名患者中，FDG-PET 在早期检测无应答者和应答者中的汇总敏感性和特异性可分别达到 80.5%（95% CI，75.9%-84.5%）和 78.8%（95% CI，74.1%-83.0%），阳性预测值和阴性预测值分别为 79.6% 和 79.5%。分别。研究结果分析表明，FDG-PET可用于评估乳腺癌患者对新辅助化疗的反应。 简介：评价氟18氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）在监测乳腺癌对新辅助化疗反应中的诊断性能。方法：通过系统 MEDLINE、Cochrane 系统评价数据库和 EMBASE 以及手动检索原始文章和综述文章中列出的参考文献来识别 2000 年 1 月至 2012 年 6 月期间在医学和肿瘤学期刊上发表的文章。通过使用诊断准确性研究评分工具的质量评估来评估纳入研究的质量。 Meta-DiSc统计软件用于计算汇总敏感性和特异性、阳性预测值和阴性预测值以及汇总受试者工作特征曲线（SROC）。结果：符合纳入标准后，15 项研究共 745 名患者被纳入研究。 FDG-PET或PET/CT的汇总敏感性和特异性分别为80.5%（95% CI，75.9%-84.5%）和78.8%（95% CI，74.1%-83.0%），阳性预测值和阴性预测值分别为79.8%和79.5%。化疗1个和2个疗程后，汇总敏感性和假阳性率分别为78.2%（95% CI，73.8%-82.5%）和11.2%；分别为 82.4%（95% CI，77.4%-86.1%）和 19.3%。结论：分析结果表明，FDG-PET在早期检测有反应者和无反应者方面具有较高的敏感性和特异性，可用于评估乳腺癌患者对新辅助化疗的反应。
The aim of this study was to evaluate the diagnostic role of fluorine- 18 fluorodeoxyglucose positron emission tomography (FDG-PET) in the monitoring of the response of breast cancers to neoadjuvant chemotherapy. From 745 patients of 15 studies, the pooled sensitivity and specificity of FDG-PET in the early detection of responders from nonresponders could reach 80.5% (95% CI, 75.9%-84.5%) and 78.8% (95% CI, 74.1%-83.0%), respectively, and the positive predictive and negative predictive values were 79.6% and 79.5%, respectively. Analysis of the findings suggest that FDG-PET could be applied in the evaluation of breast cancer response to neoadjuvant chemotherapy in patients with breast cancer.Introduction: To evaluate the diagnostic performance of fluorine- 18 fluorodeoxyglucose positron emission tomography (FDG-PET) in monitoring the response of breast cancers to neoadjuvant chemotherapy. Methods: Articles published in medical and oncologic journals between January 2000 and June 2012 were identified by systematic MEDLINE, Cochrane Database for Systematic Reviews, and EMBASE, and by manual searches of the references listed in original and review articles. Quality of the included studies was assessed by using the quality assessment of diagnosis accuracy studies score tool. Meta-DiSc statistical software was used to calculate the summary sensitivity and specificity, positive predictive and negative predictive values, and the summary receiver operating characteristics curve (SROC). Results: Fifteen studies with 745 patients were included in the study after meeting the inclusion criteria. The pooled sensitivity and specificity of FDG-PET or PET/CT were 80.5% (95% CI, 75.9%-84.5%) and 78.8% (95% CI, 74.1%-83.0%), respectively, and the positive predictive and negative predictive values were 79.8% and 79.5%, respectively. After 1 and 2 courses of chemotherapy, the pooled sensitivity and false-positive rate were 78.2% (95% CI, 73.8%-82.5%) and 11.2%, respectively; and 82.4% (95% CI, 77.4%-86.1%) and 19.3%, respectively. Conclusions: Analysis of the findings suggests that FDG-PET has moderately high sensitivity and specificity in early detection of responders from nonresponders, and can be applied in the evaluation of breast cancer response to neoadjuvant chemotherapy in patients with breast cancer.